Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 37, Status: Authorised
Xeljanz is a medicine used to treat: Xeljanz contains the active substance tofacitinib.
医薬品情報と治療ガイド
現在販売中の商品に関連する医薬品情報、適応症、用法用量、安全上の注意を掲載しています。
LEQSELVI (deuruxolitinib phosphate) tablet, film coated [Sun Pharmaceutical Industries, Inc.]
Packager: Sun Pharmaceutical Industries, Inc.
OLUMIANT (baricitinib) tablet, film coated [Eli Lilly and Company]
Boxed Warnings, Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk Medline Plus,…
